Market and Field Planned Service Outages — Northern has updated the planned service outages that will affect operating capacity within the months of November 2023 through February 2024 for the Market and Field Areas. Please refer to planned service outage notice #73723 and the Planned Service Outage Summary page for detailed information related to each outage, including the impacted allocation group(s) and/or point(s), direction of flow, normal operating capacity, estimated daily operating capacity during the outage and the anticipated impact to primary firm service. Please continue to review the Planned Service Outage and Planned Service Outage Summary sections on Northern's website for updated information.

Potential For System Underrun Limitation — With the long-range warmer than normal weather forecast and the transition of Northern’s storage fields from summer injections to winter withdrawals, the likelihood of Northern calling a System Underrun Limitation (SUL) for its entire pipeline system is at a higher probability due to high line pack conditions and Northern’s current inability to accommodate excess receipts (long gas). For further information, please review notice #73927

November 2023 Month in Review ─ Northern’s average system-weighted temperature for November 2023 was 36 F, which is 5.9% warmer than the normal average system-weighted temperature of 34 F. Northern averaged daily deliveries of 3.068 Bcf in the Market Area, compared to 3.03 Bcf in November 2022 – a 1.3% increase. A new monthly average total systemwide power plant delivery record was set in November 2023 with average deliveries of 0.506 Bcf/day, compared to 0.339 Bcf/day in November 2022 – a 49.3% increase. The previous record was 0.478 Bcf set in 2021.

Throughput Management System Mobile Version (TMS Mobile) ─ In response to customer requests, Northern has developed a mobile version of its Throughput Management System application, TMS Mobile, to provide customers with an improved experience using mobile devices such as smartphones and tablets. For further information, please review notice #74034.